🕒 Last update: loading…

Stock Iovance Biotherapeutics, Inc. IOVA

Iovance Biotherapeutics, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 212.77%

Price change 2019 → 2020: 67.63%

Price change 2020 → 2021: -58.86%

Price change 2021 → 2022: -66.53%

Price change 2022 → 2023: 27.23%

Price change 2023 → 2024: -8.98%

Price change 2024 → 2025: -63.11%

Price change 2025 → 2026: 421.25%

Price change 2026 (year to date): 464.68%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.07

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -19.47

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 3.98% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Iovance Biotherapeutics, Inc.–0.07–🔒
AbCellera Biologics Inc.–0.15+35.8 %–
Carl Zeiss Meditec AG23.10.29+8.3 %–
Virbac S.A.20.00.26+6.5 %★ 4/5
Legend Biotech Corporation–0.41+60.3 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Iovance Biotherapeutics, Inc. over the latest fiscal years.

Revenue
264 m USD
fiscal year 2025
Net income
-391 m USD
fiscal year 2025
Net margin
-148.4 %
fiscal year 2025
Market cap
3.6 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20231.2 m-444 m-37,345.4 %n/a
2024164 m-372 m-226.8 %+13,699.0 %
2025264 m-391 m-148.4 %+60.6 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Iovance Biotherapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
7.56
safe zone (above 2.99)
Piotroski Score
4 / 9
4 to 6: average accounts
Net Debt / EBITDA
0.07 x
low debt
Fiscal year20212022202320242025
Cash and investments504 m472 m280 m324 m297 m
Total Debt71.5 m85.4 m75.9 m58.3 m48.4 m
Net Debt-6.7 m-146 m-39.0 m-57.4 m-115 m
Equity622 m500 m585 m710 m699 m
Total assets777 m664 m780 m910 m913 m
Operating cash flow-228 m-293 m-362 m-353 m-302 m
Investments (capex)37.6 m20.4 m22.3 m11.1 m33.8 m
Free cash-flow-266 m-313 m-384 m-364 m-336 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-13.79 x
Price / book value4.10 x
Return on Equity (ROE)-29.7 %
Return on Invested Capital (ROIC)-25.8 %
Net margin-58.2 %
Debt / equity0.06 x
Current ratio5.20 x
Free cash-flow yield-6.4 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Iovance Biotherapeutics, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
21 analysts
Average price target
15.13 USD
from n/a to n/a, 15 targets over 12 months
Gap with the share price
+95.0 %
price 7.76 USD on 13/11/2026

Breakdown of ratings

strong buy 0buy 15hold 6sell 0strong sell 0

Average target over the last 3 months: 15.13 USD (8 targets).

Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Iovance Biotherapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
05/11/2026-0.05-0.08n/a
06/08/2026-0.11-0.13n/a
07/05/2026-0.19-0.19n/a
24/02/2026-0.18-0.22n/a
06/11/2025-0.25-0.29n/a
07/08/2025-0.33-0.29n/a

Stock splits

DateOperation
26/09/2013reverse split: 1 share for 100
26/05/2010split: 23,999 shares for 1,000

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Iovance Biotherapeutics, Inc.

Large funds tracked
20
hold the stock as of 2026Q2

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street49.0 m204 m0.0 %+180.6 %2026Q2
BlackRock37.0 m154 m0.0 %+18.9 %2026Q2
Two Sigma Investments19.0 m79.1 m0.1 %+38.9 %2026Q2
Vanguard Group27.2 m74.3 m0.0 %+13.1 %2025Q4
Geode Capital Management10.3 m43.0 m0.0 %+20.4 %2026Q2
Millennium Management8.5 m35.5 m0.0 %-9.4 %2026Q2
Goldman Sachs5.1 m21.2 m0.0 %-41.8 %2026Q2
Bank of America5.0 m20.8 m0.0 %-41.2 %2026Q2

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 15/10/2010
ISIN code
US4622601007
Workforce
838
full-time employees
Chief executive
Frederick G. Vogt

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Iovance Biotherapeutics, Inc.

What is the Iovance Biotherapeutics, Inc. share price?

Latest recorded price: 7.76 USD on 13/11/2026, for a market cap of 3.6 bn USD.

What is the revenue of Iovance Biotherapeutics, Inc.?

264 m USD for fiscal year 2025, with net income of -391 m USD (net margin -148.4 %).

What do analysts say about Iovance Biotherapeutics, Inc.?

Out of 21 analysts: 15 buy or strong buy, 6 hold, 0 sell or strong sell. Average price target: 15.13 USD, i.e. +95.0 % from the share price.

Is Iovance Biotherapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US4622601007).

How many employees does Iovance Biotherapeutics, Inc. have?

838 full-time employees according to the latest published profile.

Who runs Iovance Biotherapeutics, Inc.?

Frederick G. Vogt is the company's chief executive.

Which large funds own Iovance Biotherapeutics, Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, Two Sigma Investments, Vanguard Group, Geode Capital Management.

07

Similar stocks